• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arya Sciences Acquisition Corp IV Cl A (NQ: ARYD )

    11.55 -0.02 (-0.17%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 150,126
    Open 11.56
    Bid (Size) 11.50 (2)
    Ask (Size) 18.48 (2)
    Prev. Close 11.57
    Today's Range 11.53 - 11.56
    52wk Range 10.60 - 11.57
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
    From GENENTA SCIENCE SPA
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Friday
    During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week... 
    Via Benzinga

    Performance

    YTD
    +5.67%
    +5.67%
    1 Month
    +0.79%
    +0.79%
    3 Month
    +1.76%
    +1.76%
    6 Month
    +4.81%
    +4.81%
    1 Year
    +8.86%
    +8.86%

    More News

    Read More
    Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
    Via Benzinga
    The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
    Via Benzinga
    The Week In SPAC News - Sunday, Oct. 3
    Via Talk Markets
    Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
    Via Benzinga
    The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.